Where Tech Meets Bio
Subscribe
Sign in
Home
Weekly Highlights
Deep Dives
Features
About
Latest
Top
Discussions
Is the Future of AI Drug Discovery Hybrid?
Some field notes from the cutting edge of modern bioinformatics (CoFold Summit and Free Energy Workshop, both held recently in Barcelona, Spain).
Jun 1
•
Andrii Buvailo, PhD
19
May 2026
Is “Rescuing Failed Drugs with AI” a Category Now?
Inside the growing bet that AI can find the patients pharma's failed trials missed...
May 21
•
Andrii Buvailo, PhD
and
Roman Kasianov
30
2
3
April 2026
From Biohacking to Healthcare: The Growing Pains of the Longevity Industry
Part I: A tour of the therapeutic strategies targeting the hallmarks of aging—from cellular reprogramming to senolytics, mTOR inhibitors, and immune…
Apr 16
•
Louise von Stechow
and
BiopharmaTrend
24
2
5
Weekly Tech+Bio #81: AI Agents at the Cancer Conference
AI-pharma deals track toward a 12x increase in five years, Life Biosciences takes cell reprogramming to Phase 1, and Jeito closes Europe's largest…
Apr 14
•
Roman Kasianov
,
Andrii Buvailo, PhD
, and
BiopharmaTrend
15
2
Weekly Tech+Bio #80: Organoids on Artemis II
Anthropic's $400M AI biotech acqui-hire, CRO stocks reprice, new EMA draft, and pharma's spring acquisition spree
Apr 6
•
Roman Kasianov
,
Andrii Buvailo, PhD
, and
BiopharmaTrend
12
4
4
Everyone is Launching AI Agents. What's Being Deployed?
A check-in on biopharma's agentic AI buildout
Apr 4
•
Roman Kasianov
and
Andrii Buvailo, PhD
20
2
4
March 2026
Weekly Tech+Bio Highlights #79: A Pharma Factory in an Egg
Lilly's $2.75B generative chemistry deal and why AI research might be locked into 'hypernormal' science
Mar 30
•
Roman Kasianov
and
Andrii Buvailo, PhD
9
3
Weekly Tech+Bio Highlights #78: AI Agents Rush In
Roche and Lilly scale up pharma's biggest AI supercomputers, a billion-dollar startup unveils its virtual cell, and agents are everywhere
Mar 23
•
Roman Kasianov
,
Andrii Buvailo, PhD
, and
BiopharmaTrend
15
3
Weekly Tech+Bio Highlights #77: AI-Guided mRNA Vaccine Shrinks Dog's Cancer
Google's AI doctor passes its first clinic test, China's first take-home BCI, OpenFold3 goes fully open, and arXiv is going independent
Mar 16
•
BiopharmaTrend
,
Roman Kasianov
, and
Andrii Buvailo, PhD
10
2
Simulating the Control Arm: Virtual Patients at the Trial Bottleneck
Digital twins promise smaller, faster trials, and the regulatory scaffolding is forming. But there’s still a validation gap.
Mar 14
•
BiopharmaTrend
22
4
Weekly Tech+Bio Highlights #76: Neurons, Genomes, and Self-Driving Labs
Living neurons play DOOM, Lilly uses digital twins to scale GLP-1 production, generative genomics are now in Nature, and a rice-grain-sized retinal…
Mar 9
•
BiopharmaTrend
,
Roman Kasianov
, and
Andrii Buvailo, PhD
10
1
The €25B vs €219B Problem: Europe's Plan to Fix Biotech
Brussels is counting on new laws, sovereign AI, and billions in fresh capital to close the gap. The clock is ticking.
Mar 7
•
BiopharmaTrend
30
5
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
